Industry News
Quality Standards For Heparin Further Strengthened
May 25, 2012
To help further secure a safe supply of the widely-used blood thinner heparin, a third round of revisions to quality standards for the drug has been advanced by the U.S. Pharmacopeial Convention (USP). USP's Expert Panel on Unfractionated Heparin ended a two-day meeting on May 16th, 2012, and recommended finalization of the proposed changes... Read More
Mutation Found In Half Of All Prostate Cancers May Lead To Disease Development And Other Cancers
May 24, 2012
Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein - but no one has known how that alteration promotes cancer growth... Read More
Potential Benefits Of Novel Leukemia Treatment
May 24, 2012
Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill leukemia cells much more effectively when combined than when the drugs are administered individually... Read More
Potential Benefits Of Novel Leukemia Treatment
May 24, 2012
Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill leukemia cells much more effectively when combined than when the drugs are administered individually... Read More
New Drug To Fight Against Localized High-Risk Prostate Tumors
May 24, 2012
Men with prostate cancer could significantly benefit from a recently approved hormone-depleting drug, according to results from a phase II clinical trial. The drug - abiraterone acetate (Zytiga(R)) - can help eliminate or almost eliminate tumors in many prostate cancer patients whose cancer has not yet metastasized... Read More
New Drug To Fight Against Localized High-Risk Prostate Tumors
May 24, 2012
Men with prostate cancer could significantly benefit from a recently approved hormone-depleting drug, according to results from a phase II clinical trial. The drug - abiraterone acetate (Zytiga(R)) - can help eliminate or almost eliminate tumors in many prostate cancer patients whose cancer has not yet metastasized... Read More
Early-Life Risk Factors For Non-Hodgkin Lymphoma
May 24, 2012
Factors influencing early life non-Hodgkin lymphoma (NHL) incidence include family characteristics, high fetal growth, older maternal age, low birth order, and male gender, according to a study published in the Journal of the National Cancer Institute... Read More
Protection Against Childhood Cancers May Be Provided By Folic Acid Fortification
May 24, 2012
Researchers from the University of Minnesota and Washington University in St. Louis have found folic acid fortification of grain products in the United States may have an impact on lowering some childhood cancers... Read More
Protection Against Childhood Cancers May Be Provided By Folic Acid Fortification
May 24, 2012
Researchers from the University of Minnesota and Washington University in St. Louis have found folic acid fortification of grain products in the United States may have an impact on lowering some childhood cancers... Read More
Innovative Computer Modeling Techniques Enable Creation Of New Anti-Cancer Drug
May 24, 2012
A team of University of Hawaii Cancer Center scientists led by James Turkson, Ph.D. have created a new type of anti-cancer drug named BP-1-102. The drug, which can be orally administered, targets a key protein that triggers the development of many types of cancer including lung, breast and skin cancers... Read More
Previous Page Next Page